Tag: thrombosis

In a group of hospitalized COVID-19 patients, a therapeutic dose of low-molecular-weight heparin reduced major thromboembolic events and death. Evidence Rating Level: 1 (Excellent) Thrombotic events such as a deep vein thrombosis and pulmonary embolisms are common in patients hospitalized with COVID-19. Severely ill patients with COVID-19 often experience thrombosis despite...

1. In a group of hospitalized COVID-19 patients, a therapeutic dose of low-molecular-weight heparin reduced major thromboembolic events and death. Evidence Rating Level: 1 (Excellent) Thrombotic events such as a deep vein thrombosis and pulmonary embolisms are common in patients hospitalized with COVID-19. Severely ill patients with COVID-19 often experience thrombosis...

1. Patients with chronic limb ischemia (CLI) treated with low-intensity pulsed ultrasound (LIPUS) had lower rates of amputation compared to those treated under standard care without LIPUS, after 5-year follow-up. 2. No difference in 5-year rates of survival or major adverse cardiovascular events were found between CLI patients treated with...

1. Dual treatment with ticagrelor and aspirin is both safe and effective for patients with moderate ischemic stroke, beyond the benefits of aspirin monotherapy Evidence Rating Level: 2 (Good) Study Rundown: Dual antiplatelet therapy (DAPT) is a well-studied approach to the treatment of ischemic stroke and transient ischemic attack (TIA). Studies...

1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy. 2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Patients who receive percutaneous...

1. There was no significant difference found in thrombosis or bleeding outcomes for patients with atrial fibrillation or mechanical heart valves, where patients were randomly assigned to receive dalteparin or a placebo after an invasive procedure requiring cessation of warfarin. Evidence Rating Level: 1 (Excellent) Patients with atrial fibrillation or mechanical...

1. Roughly 33.8% of patients with atrial fibrillation and/or venous thromboembolism undergoing treatment with a direct oral anticoagulant (DOAC) were also being treated with aspirin without a clear indication. 2. Patients being treated with DOAC and aspirin experienced significantly more bleeding events and hospitalizations, compared to DOAC monotherapy. Evidence Rating Level:...

1. In this cross-sectional study, women with premature atherosclerotic cardiovascular disease (ASCVD) and extremely premature ASCVD were less likely to receive antiplatelet agents or statins than men. Evidence level rating: 2 (Good) Secondary prevention guidelines highlight the importance of initiation antiplatelet and statin therapy in patients with ASCVD, especially...

P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor 1. In patients undergoing percutaneous coronary intervention, 3-month dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy showed comparable cardiovascular outcomes to 12-month DAPT. Evidence Rating Level: 2 (Good) Several randomized trials have showed that after percutaneous coronary intervention (PCI),...